GLP-1 receptor agonists work by: Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps regulate blood sugar levels Slowing gastric emptying , meaning food remains in the stomach longer, promoting feelings of fullness Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger signals and food cravings Decreasing glucagon secretion , which helps prevent excessive glucose production by the liver Most GLP-1 agonists are administered via subcutaneous injection, typically once weekly or once daily depending on the specific formulation, though oral semaglutide (Rybelsus) is also available
The maximum amplitude of the response ( b ) and activation rates ( c ) are presented as bar graphs
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Sleep Science, 8 (3), 143-152
What is the purity of ONE BPC-157
Vigil, P., et al